RayzeBio Revenue and Competitors
Estimated Revenue & Valuation
- RayzeBio's estimated annual revenue is currently $18.6M per year.
- RayzeBio's estimated revenue per employee is $155,000
- RayzeBio's total funding is $258M.
Employee Data
- RayzeBio has 120 Employees.
- RayzeBio grew their employee count by 9% last year.
RayzeBio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $1.1M | 7 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 150% | N/A | N/A |
#5 | $1.4M | 9 | 0% | N/A | N/A |
#6 | $11.5M | 74 | -12% | N/A | N/A |
#7 | $0.4M | 275 | 10% | $236.7M | N/A |
#8 | $4M | 51 | -74% | $160M | N/A |
#9 | $2.5M | 16 | 33% | N/A | N/A |
#10 | $3.3M | 21 | -12% | N/A | N/A |
What Is RayzeBio?
Leader in targeted radiopharmaceuticals to improving cancer patient survival. Broad pipeline of innovative drugs against solid tumor targets
keywords:N/A
$258M
Total Funding
120
Number of Employees
$18.6M
Revenue (est)
9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
RayzeBio News
San Diego-based RayzeBio, a pharmaceuticals company which says it is developing targeted radiopharmaceutical drugs for cancer, has raised $108M in its Series C funding. The company said it has now raised a total of $258M. The new funding was led by Venrock Healthcare Capital Partners and also in ...
RayzeBio, Inc., which is discovering and developing a broad pipeline of innovative targeted radiopharmaceutical drugs for cancer, today announced a $108 million Series C financing led by Venrock Healthcare Capital Partners alongside new investors Perceptive Advisors, Vivo Capital, Acuta Capital ...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $122.2M | 120 | 2% | $85.9M |
#2 | $18M | 120 | -1% | N/A |
#3 | $32.4M | 120 | 3% | N/A |
#4 | $14.4M | 120 | -2% | N/A |
#5 | $16.8M | 120 | 14% | $20.9M |
RayzeBio Executives
| Name | Title |
|---|---|
| Arvind Kush | Chief Financial Officer |
| Deborah Charych | Scientific Founder, Chief Technology Officer, Advisor |
| Susan Moran | Chief Medical Officer |
| Ken Song | President and CEO |
| Kimberly Ma | SVP of Clinical Operations |
| Derek Cole | Senior Vice President Chemistry, Head of Discovery |
| Eric Bischoff | Senior Vice President, Development and Operations at RayzeBio, Inc. |
| Juan Li | VP, Biometrics |
| Ken Song | President and CEO |
| Eric Bischoff | SVP Development & Operations |
| Gary Li | Senior Vice President, Biology & Translational Medicine |
| Nicholas Smith | SVP, Chemistry Innovation |
| Abhi Bhat | SVP, Chemistry & Head of Discovery |